Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.33 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140425 | 1.00 | CTSA (0.38) | CTSAGRM5ABL1GRIN2BGRIN1 | |
| SCHEMBL2143057 | 0.92 | CTSA (0.36) | CTSAGRM5KCNH2 | |
| SCHEMBL2140379 | 0.92 | CTSA (0.36) | CTSAGRM5KCNH2 | |
| SCHEMBL2140764 | 0.90 | CTSA (0.34) | CTSAGRM5GRIN2BKCNH2 | |
| SCHEMBL2140756 | 0.90 | CTSA (0.34) | CTSAGRM5GRIN2BKCNH2 | |
| SCHEMBL2141760 | 0.90 | KCNH2 (0.42) | CTSAGRM5GRIN2BKCNH2 | |
| SCHEMBL2143467 | 0.90 | KCNH2 (0.42) | CTSAGRM5GRIN2BKCNH2 | |
| SCHEMBL2139165 | 0.89 | CYP11B1 (0.40) | CTSA | |
| SCHEMBL2143426 | 0.89 | CYP11B1 (0.40) | CTSA | |
| SCHEMBL2140809 | 0.88 | ABL1 (0.38) | ABL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148407-B2 | Compounds derived from 5-thioxylose and their use in therapeutics | LABORATORIES FOURNIER S.A. (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | INVENTIVA (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1861411-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100413-A9 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | FOURNIER LAB SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006100413-A2 | NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THERAPEUTIC USE THEREOF | LABORATOIRES FOURNIER S.A. (FR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293768-A1 | Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics | TPMT, STS, TBXAS1 | CTSA 1743/4885GRM5 1055/4885ABL1 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.